ASCO

AK104 plus Chemotherapy Potential New First-Line Treatment for Patients with Advanced Gastric Cancer

Interim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 superagonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer. Read More ›

Neoadjuvant Enfortumab Vedotin Appears Promising in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin

Continuous enzalutamide (Xtandi) treatment in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer who had disease progression on enzalutamide alone, according to results from the phase 3b PRESIDE clinical trial. Read More ›

Neoadjuvant Checkpoint Inhibitor plus TKI for Localized RCC: Encouraging Disease-Free Survival

Neoadjuvant enfortumab vedotin (Padcev) showed promising antitumor activity in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin therapy, according to preliminary findings from cohort H of the phase 1b/2 EV-103 clinical trial. Read More ›

Zanidatamab Demonstrates Durable Antitumor Activity in HER2‑Expressing Gastric Cancers

The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial. Read More ›

By Wayne Kuznar

ASCO, Gastrointestinal Cancers

TON - April 2021 Vol 14, No 2

The HER2-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing clinical trial of patients with HER2-expressing biliary tract cancer or gastroesophageal adenocarcinoma. Read More ›

Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation

By Wayne Kuznar

TON - April 2021 Vol 14, No 2

Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Read More ›

A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies

By Wayne Kuznar

TON - April 2020, Vol 13, No 2

San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process. Read More ›

Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment

By Phoebe Starr